» Articles » PMID: 34858270

Couple Therapy With MDMA-Proposed Pathways of Action

Overview
Journal Front Psychol
Date 2021 Dec 3
PMID 34858270
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

MDMA's first identified potential as a therapeutic catalyst was for couple therapy. Early work in the 1970s and 1980s explored its potential amongst seasoned psychotherapists and their clients. With the completion of the first pilot trial of MDMA-assisted psychotherapy with couples for PTSD, and as the possibility of conducting MDMA-assisted psychotherapy trials expands due to new regulatory frameworks, we have an opportunity to explore and investigate how and why MDMA-assisted couples therapy works. This theoretical paper will explore the neurobiological and neurochemical effects of MDMA in a relational context, the emotional, behavioral, cognitive and somatic effects within a dyadic frame, and how empathy, communication, perception of social connection/support, non-avoidance, openness, attachment/safety, bonding/social intimacy and relationship satisfaction, are all impacted by MDMA, and can be harnessed to facilitate systems-level and interpersonal healing and growth. A model to support MDMA-assisted couple therapy is introduced, and future directions, including implications for intervention development and delivery, will be elucidated.

Citing Articles

The conceptual framework for the therapeutic approach used in phase 3 trials of MDMA-assisted therapy for PTSD.

ODonnell K, Okano L, Alpert M, Nicholas C, Thomas C, Poulter B Front Psychol. 2024; 15:1427531.

PMID: 39559692 PMC: 11571099. DOI: 10.3389/fpsyg.2024.1427531.


A novel framework for ketamine-assisted couple therapy.

Khalifian C, Rashkovsky K, Mitchell E, Bismark A, Wagner A, Knopp K Front Psychiatry. 2024; 15:1376646.

PMID: 39193577 PMC: 11347343. DOI: 10.3389/fpsyt.2024.1376646.


Preliminary evidence for the importance of therapeutic alliance in MDMA-assisted psychotherapy for posttraumatic stress disorder.

Zeifman R, Kettner H, Ross S, Weiss B, Mithoefer M, Mithoefer A Eur J Psychotraumatol. 2024; 15(1):2297536.

PMID: 38174611 PMC: 10769553. DOI: 10.1080/20008066.2023.2297536.


Co-use of MDMA with psilocybin/LSD may buffer against challenging experiences and enhance positive experiences.

Zeifman R, Kettner H, Pagni B, Mallard A, Roberts D, Erritzoe D Sci Rep. 2023; 13(1):13645.

PMID: 37608057 PMC: 10444769. DOI: 10.1038/s41598-023-40856-5.


Psychedelic therapy in the treatment of addiction: the past, present and future.

Zafar R, Siegel M, Harding R, Barba T, Agnorelli C, Suseelan S Front Psychiatry. 2023; 14:1183740.

PMID: 37377473 PMC: 10291338. DOI: 10.3389/fpsyt.2023.1183740.


References
1.
Carhart-Harris R, Wall M, Erritzoe D, Kaelen M, Ferguson B, De Meer I . The effect of acutely administered MDMA on subjective and BOLD-fMRI responses to favourite and worst autobiographical memories. Int J Neuropsychopharmacol. 2013; 17(4):527-40. DOI: 10.1017/S1461145713001405. View

2.
Young M, Norrholm S, Khoury L, Jovanovic T, Rauch S, Reiff C . Inhibition of serotonin transporters disrupts the enhancement of fear memory extinction by 3,4-methylenedioxymethamphetamine (MDMA). Psychopharmacology (Berl). 2017; 234(19):2883-2895. PMC: 5693755. DOI: 10.1007/s00213-017-4684-8. View

3.
Feduccia A, Mithoefer M . MDMA-assisted psychotherapy for PTSD: Are memory reconsolidation and fear extinction underlying mechanisms?. Prog Neuropsychopharmacol Biol Psychiatry. 2018; 84(Pt A):221-228. DOI: 10.1016/j.pnpbp.2018.03.003. View

4.
Bedi G, Hyman D, de Wit H . Is ecstasy an "empathogen"? Effects of ±3,4-methylenedioxymethamphetamine on prosocial feelings and identification of emotional states in others. Biol Psychiatry. 2010; 68(12):1134-40. PMC: 2997873. DOI: 10.1016/j.biopsych.2010.08.003. View

5.
Wolff K, Tsapakis E, Winstock A, Hartley D, Holt D, Forsling M . Vasopressin and oxytocin secretion in response to the consumption of ecstasy in a clubbing population. J Psychopharmacol. 2006; 20(3):400-10. DOI: 10.1177/0269881106061514. View